GT Biopharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014
Cash & Equivalents	1.08	5.68	8.97	5.3	0.04	0.07	0.59	0.02	0.05	0.86
Short-Term Investments	12.89	10.84	23.01	0	0	0	0	0	0	0
Cash & Cash Equivalents	13.97	16.52	31.98	5.3	0.04	0.07	0.59	0.02	0.05	0.86
Cash Growth	-15.41%	-48.35%	503.72%	13142.50%	-44.44%	-87.69%	2978.95%	-59.57%	-94.50%	-
Other Current Assets	0.08	0.05	0.19	0.36	0.23	0.02	-0.01	0	0	0.03
Total Current Assets	14.06	16.56	32.17	5.66	0.27	0.09	0.58	0.02	0.05	0.88
Property, Plant & Equipment	0.05	0.17	0	0	0.11	0.04	0.01	0	0.01	0.01
Goodwill and Intangibles	0	0	0	0	0	25.26	253.78	0	0	0
Other Long-Term Assets	0	0.01	0	0	0.01	0.01	0.01	0	0	0
Total Long-Term Assets	0.05	0.17	0	0	0.12	25.31	253.79	0	0.01	0.01
Total Assets	14.11	16.74	32.17	5.66	0.4	25.4	254.37	0.03	0.05	0.89
Accounts Payable	4.33	3.14	8.19	2.24	1.94	1.76	2.55	2.1	0.89	0.41
Current Debt	0.06	0.11	0.03	26.33	13.36	10.8	0.03	11.72	8.34	2.03
Other Current Liabilities	2.25	1.69	2.04	6.52	4.41	1.46	0.1	5.13	40.67	27.38
Total Current Liabilities	6.63	4.94	10.26	35.09	19.71	14.03	2.68	18.95	49.91	29.83
Long-Term Debt	0	0.06	0	0	0	0	0	0	0.71	0.63
Total Long-Term Liabilities	0	0.06	0	0	0	0	0	0	0.71	0.63
Total Liabilities	6.63	5	10.26	35.09	19.71	14.03	2.68	18.95	50.62	30.46
Total Debt	0.06	0.17	0.03	26.33	13.36	10.8	0.03	11.72	9.06	2.67
Debt Growth	-66.67%	461.29%	-99.88%	97.14%	23.64%	34751.61%	-99.74%	29.44%	239.43%	-
Retained Earnings	-682.07	-674.47	-653.58	-595.8	-567.33	-528.69	-269.5	-124.65	-134.42	-112.96
Shareholders' Equity	7.48	11.73	21.91	-29.43	-19.14	11.54	251.86	-18.76	-50.4	-29.41
Net Cash / Debt	13.91	16.34	31.95	-21.04	-13.32	-10.73	0.55	-11.7	-9.01	-1.81
Net Cash / Debt Growth	-14.86%	-48.84%	-	-	-	-	-	-	-	-
Net Cash Per Share	10.32	15.39	34.04	-143.92	-118.07	-108.94	16.85	-73143.75	-1918.85	-397.24
Working Capital	7.42	11.62	21.91	-29.43	-19.43	-13.94	-2.1	-18.93	-49.86	-28.95
Book Value Per Share	5.55	11.05	23.34	-201.36	-169.69	117.14	7659.91	-117420.57	-10734.42	-6442.17

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).